Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.

Anthony B El-KhoueiryJames ClarkeTobias NeffTim CrossmanNirav RatiaChetan RathiPaul NotoAarti TarkarIgnacio Garrido-LagunaEmiliano CalvoJordi Rodon Ahnert Ben TranPeter J O'DwyerAdam CukerAlbiruni R Abdul Razak

Published in: British journal of cancer (2023)

NCT03666988.

Keyphrases

open label
signaling pathway
pi k akt
double blind
placebo controlled
cell proliferation